[144] Surgery Partners, Inc. SEC Filing

Rhea-AI Filing Summary

Surgery Partners, Inc. (SGRY) Form 144 notice reports an intended sale of 10,613 common shares through UBS Financial Services on NASDAQ with an aggregate market value of $234,547.30. The securities were acquired the same day as equity compensation via an equity option exercise. The filer reports numerous recent open-market sales by Wayne DeVeydt totaling multiple transactions between August and September 2025, including sales of 100,000 and 150,000 share lots. The filing affirms the seller does not possess undisclosed material adverse information. The reported number of shares outstanding is 128,209,410, providing context for the relative scale of the transactions.

Positive

• Compliance disclosure provided with broker, transaction details, and seller attestation as required under Rule 144
• Acquisition method disclosed (equity option exercise) clarifies the origin of shares to be sold

Negative

• Frequent large insider sales by Wayne DeVeydt in August–September 2025 (multiple transactions including 100,000+ and 150,000 share lots) increase available insider supply
• No explanatory context for clustered insider sales is provided beyond the standard attestation

Insights

Securities Analyst

TL;DR: Multiple large insider sales and a current planned sale of 10,613 shares signal notable insider liquidity events.

The filing shows an immediate acquisition by exercise of equity compensation and a near-term sale notice for 10,613 shares valued at $234,547.30 to be executed through UBS on NASDAQ. The record of repeated open-market sales by Wayne DeVeydt across August and September 2025, including several 100,000+ share transactions, represents substantial insider selling activity. With 128.2 million shares outstanding, these transactions are measurable but do not, on their own, disclose any change to company operations or financial performance. The disclosure is routine under Rule 144 but important for monitoring insider supply into the market.

Corporate Governance Expert

TL;DR: Filing is a standard compliance disclosure; repeated large sales warrant attention to insider disposition patterns.

The Form 144 entries are compliant with Rule 144 requirements: they identify the broker, class of security, acquisition method (equity option exercise), and multiple recent sales with gross proceeds listed. The seller’s attestation about lack of undisclosed material adverse information is present. From a governance perspective, clustered and frequent sales by a named insider could reflect personal liquidity needs or planned diversification, but the document provides no explanation beyond the required representations. No governance violation or undisclosed transaction terms are evident in the filing.

09/19/2025 - 04:37 PM

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
common	UBS Financial Services Inc 1000 Harbor Blvd 3rd Floor Weehawken NJ 07086	10613	234547.3	128209410	09/19/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
common	09/19/2025	equity compensation	Surgery Partners, Inc.			10613	09/19/2025	equity option exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Wayne DeVeydt 9910 Cumberland Drive Fishers IN 46037	common	08/21/2025	100000	2299011
Wayne DeVeydt 9910 Cumberland Drive Fishers IN 46037	common	08/26/2025	25000	572717
Wayne DeVeydt 9910 Cumberland Drive Fishers IN 46037	common	08/27/2025	11865	271756
Wayne DeVeydt 9910 Cumberland Drive Fishers IN 46037	common	09/02/2025	25000	562150
Wayne DeVeydt 9910 Cumberland Drive Fishers IN 46037	common	09/03/2025	25000	560251
Wayne DeVeydt 9910 Cumberland Drive Fishers IN 46037	common	09/04/2025	25000	562756
Wayne DeVeydt 9910 Cumberland Drive Fishers IN 46037	common	09/05/2025	25000	563682
Wayne DeVeydt 9910 Cumberland Drive Fishers IN 46037	common	09/08/2025	2014	45207
Wayne DeVeydt 9910 Cumberland Drive Fishers IN 46037	common	09/11/2025	100000	2200741
Wayne DeVeydt 9910 Cumberland Drive Fishers IN 46037	common	09/12/2025	28700	628929
Wayne DeVeydt 9910 Cumberland Drive Fishers IN 46037	common	09/16/2025	25000	541518
Wayne DeVeydt 9910 Cumberland Drive Fishers IN 46037	common	09/17/2025	85785	1873875
Wayne DeVeydt 9910 Cumberland Drive Fishers IN 46037	common	09/18/2025	150000	3294425

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Surgery Partners (SGRY) report in this Form 144?

The filing notifies an intended sale of 10,613 common shares through UBS on NASDAQ valued at $234,547.30; acquisition was by equity option exercise on the same date.

Who has been selling Surgery Partners shares recently according to the filing?

The filing lists multiple open-market sales by Wayne DeVeydt between August and September 2025, including several large lots (e.g., 100,000 and 150,000 share transactions).

How many shares of Surgery Partners are outstanding per the Form 144?

The filing reports 128,209,410 shares outstanding.

What acquisition method produced the shares proposed for sale?

The shares to be sold were acquired on 09/19/2025 via equity compensation (equity option exercise) as stated in the filing.

Does the filer state they possess undisclosed material information?

The signer represents that they do not know any material adverse information about the issuer that has not been publicly disclosed.